Baseline demographic and clinical characteristics of the cohort and stratified by use of androgen deprivation therapy (ADT)
Entire cohort | ADT use during follow-up* | ||
---|---|---|---|
Characteristic | N, % | Any ADT, % | No ADT, % |
Total | 20 310 | 10 250 (50.5) | 10 060 (49.5) |
Age, years (mean, SD) | 71.2 (9.1) | 72.8 (8.2) | 68.6 (9.1) |
Body mass index, n (%) | |||
<25 kg/m2 | 6386 (31.4) | 3257 (31.8) | 3129 (31.1) |
25–30 kg/m2 | 9069 (44.7) | 4397 (42.9) | 4672 (46.4) |
≥30.0 | 3785 (18.6) | 2001 (19.5) | 1784 (17.7) |
Unknown | 1070 (5.3) | 595 (5.8) | 475 (4.7) |
Smoking status, n (%) | |||
Current | 2249 (11.1) | 1215 (11.9) | 1034 (10.3) |
Past | 7880 (38.8) | 4147 (40.6) | 3733 (37.1) |
Never | 9639 (47.5) | 4596 (44.8) | 5043 (50.1) |
Unknown | 542 (2.7) | 292 (2.9) | 250 (2.5) |
Alcohol-related disorders, n (%) | 1899 (9.4) | 937 (9.1) | 962 (9.6) |
Prostate-specific antigen, n (%) | |||
<4 ng/mL | 1192 (5.9) | 250 (2.4) | 942 (9.4) |
4–10 ng/mL | 6459 (31.8) | 1814 (17.7) | 4645 (46.2) |
≥10 ng/mL | 9704 (47.8) | 6673 (65.1) | 3031 (30.1) |
Unknown | 2955 (14.6) | 1513 (14.8) | 1442 (14.3) |
High-risk season, n (%) | 10 203 (50.2) | 5079 (49.6) | 5124 (50.9) |
Previous cancer, n (%) | 2348 (11.6) | 1223 (11.9) | 1125 (11.2) |
COPD, n (%) | 2617 (12.9) | 1447 (14.1) | 1170 (11.6) |
Asthma, n (%) | 2366 (11.7) | 1160 (11.3) | 1206 (12.0) |
Bronchitis, n (%) | 1540 (7.6) | 854 (8.3) | 686 (6.8) |
Bronchiectasis, n (%) | 41 (0.2) | 18 (0.2) | 23 (0.2) |
Immunosuppressive agents, n (%) | 167 (0.8) | 81 (0.8) | 86 (0.9) |
Inhaled bronchodilators, n (%) | 2519 (12.4) | 1341 (13.1) | 1178 (11.7) |
Inhaled corticosteroids, n (%) | 2003 (9.9) | 1067 (10.4) | 936 (9.3) |
Oral corticosteroids, n (%) | 1182 (5.8) | 625 (6.1) | 557 (5.5) |
Non-topical antibiotics, n (%) | 8719 (42.9) | 4479 (43.7) | 4240 (42.2) |
Influenza vaccines, n (%) | 10 444 (51.4) | 6040 (58.9) | 4404 (43.8) |
Pneumococcal vaccines, n (%) | 1258 (6.2) | 691 (6.7) | 567 (5.6) |
*ADT use in the first six months during follow-up.